Inhibits cell wall synthesis by binding D-Ala-D-Ala and also disrupts cell membrane integrity
Interactions
No curated interaction pairs are recorded for Oritavancin. This is not a statement that none exist — check a full interaction reference before combining.
Common adverse effects
Nausea
Headache
Vomiting
Infusion site reactions
Pharmacokinetics
Half-life
245 hours
Protein binding
85%
Pregnancy & lactation
Not recorded for Oritavancin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.
Sources
Assembled from: drug index, curated drug database.
